,0,1
0,cautionary notice,9.0
1,activation markers,9.0
2,visible swelling,9.0
3,retained interests,9.0
4,sequence peptides,9.0
5,biomarker test,9.0
6,cr,9.0
7,scientific officer,8.857142857142858
8,direct offering,8.833333333333334
9,medicines agency,8.8
10,circulating serum,8.777777777777779
11,withholding taxes,8.746268656716417
12,os status,8.6
13,preventative vaccines,8.523809523809524
14,multiple functions,8.513513513513514
15,control,8.5
16,reserved ruling,8.5
17,employee payroll taxes,8.449972360420123
18,conditional licensure,8.428571428571429
19,vice president,8.428571428571429
20,track product,8.41891891891892
21,security deposit,8.414285714285715
22,published literature,8.4
23,allege counts,8.384615384615385
24,operable refractory/recurrent disease,8.329113924050633
25,residual disease,8.329113924050633
26,financial institutions,8.324675324675326
27,financial officer,8.324675324675326
28,capital resources,8.3
29,marketing authorization application,8.3
30,side effects,8.285714285714285
31,control group,8.285714285714285
32,profitability,8.25
33,obligations,8.2389486260454
34,improved survival,8.217391304347826
35,occurrence rate,8.216763792821743
36,additional capital,8.214285714285715
37,bacterial vector,8.204081632653061
38,bank deposit accounts,8.2
39,health applications,8.19047619047619
40,capital outlays,8.188888888888888
41,executive officer,8.166666666666666
42,direct offerings,8.142857142857142
43,income tax,8.135261194029852
44,protein,8.125
45,enrichment claim,8.105263157894736
46,orphan drug designation,8.084745762711865
47,debt securities,8.070048309178745
48,protocol assessment,8.05982905982906
49,operating officer,8.058823529411764
50,balance sheets,8.05
51,disease control rate,8.017638514214568
52,patented technologies,8.0
53,tumor driver genes,8.0
54,tumor models,8.0
55,related symptoms,7.985994397759104
56,dose levels,7.969125902165196
57,cancer institute,7.955645161290322
58,steering committee,7.951219512195122
59,regulatory opportunities,7.95
60,multiple targets,7.942084942084942
61,service period,7.9411764705882355
62,osteosarcoma,7.931818181818182
63,losses,7.919512195121952
64,recurring accruals,7.914285714285715
65,related projects,7.902661064425771
66,conversion features,7.897435897435898
67,counts,7.884615384615385
68,cancer,7.876099706744868
69,balance sheets,7.873529411764707
70,footnotes thereto,7.819327731092438
71,accounting policies,7.814814814814815
72,expert committee,7.80836236933798
73,poor outcomes,7.800000000000001
74,recurrent/refractory cervical cancer,7.794281524926687
75,cervical cancer,7.794281524926687
76,accounting pronouncements,7.783950617283951
77,stock units,7.782258064516129
78,related symptoms,7.7637721755368805
79,lessees,7.753623188405797
80,lease rate,7.736143637782982
81,immune activation,7.733716475095785
82,unjust enrichment,7.723684210526316
83,expanded development,7.715789473684211
84,doubtful accounts,7.7
85,commercial success,7.7
86,net income,7.697761194029851
87,manufacturing responsibilities,7.6923076923076925
88,cash position,7.674107142857142
89,monoclonal antibody,7.666666666666667
90,multiple constructs,7.656370656370656
91,biologics license application,7.648837209302326
92,nol tax sales,7.6375
93,medicinal product,7.633204633204633
94,prostate cancer,7.626941457586618
95,damages,7.625
96,emerging markets,7.625
97,modification,7.617283950617285
98,interest rates,7.6159340659340655
99,vice president,7.595238095238095
100,patient dataset,7.588235294117647
101,sponsored trials,7.563172043010753
102,therapeutic partner,7.561904761904762
103,average number,7.560975609756097
104,disease progression,7.559883154819864
105,consumption,7.5588235294117645
106,competitive supply,7.555555555555555
107,accounting standards,7.547586980920315
108,product candidates,7.540942728442728
109,oncology group,7.523504273504273
110,related reactions,7.519327731092437
111,retrospective approach,7.510869565217391
112,month survival rate,7.5059158945117606
113,dose level,7.5
114,interest income,7.494647640916298
115,amounts previously accrued,7.491386735572782
116,prior chemo,7.472727272727273
117,performance obligations,7.470430107526882
118,performance obligations,7.470430107526882
119,common stock,7.462980956082394
120,conditional power,7.461538461538462
121,cervical cancer,7.4464554379701635
122,art manufacturing facility,7.4423076923076925
123,company shareholder,7.435114503816794
124,company,7.435114503816794
125,complete response,7.417460317460318
126,tumor targets,7.414285714285715
127,securities exchange act,7.406432748538012
128,cat certification procedure,7.4
129,response rate,7.3974134790528225
130,regulatory approvals,7.392857142857142
131,tolerated dose,7.388888888888889
132,damages,7.375
133,cash flows,7.364583333333333
134,retrospective approach,7.362060041407867
135,fusion protein,7.36082910321489
136,drug stability studies,7.360607831677383
137,scientific research,7.360498561840844
138,data,7.359937402190924
139,patent term extension,7.3527272727272734
140,product license request,7.339184699649817
141,liquid investments,7.336805555555555
142,stock options,7.3352850198851085
143,cash settlement provision,7.314583333333333
144,cancer immunotherapy agent,7.307389347336834
145,invasive stage,7.303921568627451
146,license fees,7.301614987080103
147,measurements defines fair,7.3
148,exercise prices,7.297435897435898
149,clinical trial,7.296108895599456
150,conversion prices,7.294871794871795
151,cancer programs,7.278152492668623
152,savings account balance,7.274358974358975
153,states department,7.271062271062271
154,conditional licensure,7.269480519480519
155,exclusive rights,7.269230769230769
156,exercise price,7.2518518518518515
157,significant losses,7.250376392652815
158,bevacizumab pre,7.25
159,papilloma virus,7.241379310344827
160,disease progression,7.22654982148653
161,previously treated metastatic,7.214650343682601
162,registrational opportunities,7.212820512820513
163,credit losses,7.21199339812947
164,adverse events,7.21110262286733
165,balance sheet arrangements,7.208333333333334
166,significant unmet medical,7.202192868859536
167,financial statements,7.201639850943847
168,front payment,7.195475113122172
169,risk factor,7.186325469812075
170,tumor model,7.181818181818182
171,american countries,7.180952380952381
172,operational costs,7.176452020202021
173,osteosarcoma specialists,7.173197492163009
174,additional claims,7.164285714285715
175,duty claim,7.157894736842105
176,potential applications,7.151866151866152
177,collaborations,7.151282051282051
178,prior period,7.141176470588236
179,risk mitigation measures,7.140255009107468
180,property rights,7.138461538461538
181,cancer society,7.135253456221198
182,safety profile,7.124053581828771
183,llo,7.115633074935401
184,line induction chemotherapy,7.113636363636363
185,cancer therapy,7.100486431131592
186,targeted therapies,7.095238095238095
187,risk,7.0945033751205395
188,specific performance,7.083333333333334
189,income tax expense,7.081927860696517
190,cell responses,7.073671497584542
191,compensation cost,7.071464483229189
192,impairment model,7.070707070707071
193,credit losses,7.069136255272327
194,product license application,7.067756128221244
195,clinical sites,7.052957680617256
196,determined fees,7.05
197,antibiotic treatment,7.0476190476190474
198,bevacizumab treatment,7.034632034632035
199,treatment interventions,7.030197444831591
200,clinical study,7.0282324058919805
201,cervical cancer,7.028047758692919
202,free survival,7.022695704588935
203,complete response,7.017460317460317
204,liability valuation,7.007936507936508
205,axalimogene filolisbac,7.007575757575758
206,regulatory incentives,7.003623188405797
207,significant revenues,6.989197530864198
208,notes thereto,6.988038277511962
209,general allegations,6.975065436010469
210,plaintiff,6.966666666666667
211,escalation phase,6.953759723422644
212,fully funded exclusively,6.952380952380952
213,promissory notes,6.94608023555392
214,trial programs,6.933826017187545
215,free survival,6.924351011307533
216,recommended combination,6.917721518987342
217,interest rates,6.917521367521368
218,upfront fees,6.917483660130719
219,stable disease,6.913240908177617
220,effect,6.906976744186046
221,taxes,6.889125799573561
222,tumor burden,6.888888888888889
223,therapeutic cancer,6.888680875576037
224,klebsiella lung infection,6.877192982456141
225,credit risk,6.869949615995058
226,operation support,6.86969696969697
227,osteosarcoma osteosarcoma,6.863636363636363
228,scholes model,6.848484848484848
229,treatment regimen,6.838095238095239
230,breast cancer,6.830645161290322
231,additional capital,6.829670329670329
232,corporate matters,6.8224043715847
233,treatment options,6.818003913894325
234,estimate,6.814285714285714
235,regulatory obligations,6.81100981767181
236,cervical cancer,6.794281524926687
237,epitope immunotherapies,6.787912436548224
238,repeat cycles,6.78108003108003
239,1b study,6.780682800345723
240,cell carcinoma,6.7700000000000005
241,capital management,6.768085106382978
242,tumor responses,6.754782608695653
243,biocon,6.754249815225425
244,adequate safety,6.753465346534653
245,project milestones,6.7479716024340775
246,survival time,6.741200828157351
247,drug controller general,6.740483467629898
248,development tax credits,6.736622807017545
249,salary,6.733516483516484
250,accounting standards,6.729405162738496
251,tumor response,6.70888888888889
252,compensation cost,6.696299188684975
253,quality trial,6.688206160037146
254,immune microenvironment,6.678160919540231
255,financial information,6.677616501145913
256,axalimogene filolisbac,6.674242424242424
257,anal cancer,6.6735023041474655
258,past employees,6.661616161616161
259,development program,6.659406494960806
260,performance bonus,6.642857142857142
261,communication,6.631372549019607
262,reporting date,6.629032258064516
263,clinical data,6.624899452707285
264,clinical activities,6.623723122072352
265,share settlement,6.6069767441860465
266,significant investments,6.59782848324515
267,revenue arrangements,6.594270833333333
268,adverse effect,6.594047619047619
269,development programs,6.593277462702742
270,patent costs,6.578643578643579
271,fda feedback,6.575581395348838
272,related expense,6.573686705451411
273,treatment regimen,6.561904761904762
274,intangible assets,6.552134646962234
275,worldwide license,6.53793977340489
276,concurrent chemotherapy,6.5348692403486925
277,based compensation,6.534112808756659
278,safety endpoints,6.521758029461482
279,escalation portion,6.5173697270471465
280,synonymous mutations,6.5166666666666675
281,efficacy endpoints,6.513419913419913
282,stock,6.50914882081865
283,derivative complaint,6.506827731092438
284,considered possibly related,6.497105508870215
285,expression,6.493714285714286
286,enrollment,6.491758241758243
287,patients,6.49153605015674
288,sale debt securities,6.470048309178744
289,product development capabilities,6.468041725936462
290,deferred revenue,6.4609375
291,payment accounting,6.458882284601405
292,infusion,6.457575757575758
293,neck cancer,6.457115749525617
294,clinical trials,6.454338083895191
295,adverse events,6.4505984211866565
296,research organizations,6.446972725974582
297,llo cancer immunotherapy,6.446278236225723
298,milestone,6.445652173913043
299,liability warrants,6.437150701049123
300,promissory note,6.430014430014429
301,testing axalimogene,6.424242424242424
302,cash bonus,6.424107142857142
303,balance sheet date,6.420698924731183
304,holding period,6.416176470588235
305,adjuvant axalimogene,6.415470494417863
306,trial expenses,6.412571871875516
307,accounting pronouncements,6.412522045855379
308,financial statements,6.406681867750571
309,future payments,6.404616724738676
310,biologics research,6.4033557046979865
311,amended lease,6.4018510225406775
312,notification,6.3998203861697345
313,employee excellence awards,6.394901394901394
314,cell carcinoma,6.394390243902439
315,drug development pipeline,6.383868569729408
316,common stock,6.366206762534007
317,metastatic disease,6.362880157816867
318,development payments,6.353308933985197
319,annual periods,6.3508536889332
320,cancer recurrence,6.349837080482242
321,laboratory space,6.34841628959276
322,cost spending,6.344444444444445
323,cervical cancer,6.339736070381232
324,legal proceedings,6.328571428571428
325,minimum payments,6.318902439024391
326,cancer,6.313284050179211
327,net loss,6.304878048780488
328,specific antigen,6.296296296296296
329,obligations table,6.295668202764976
330,stock options,6.265675512245041
331,trial collaboration,6.2624550494456095
332,common shares,6.259901777196764
333,share,6.235548172757475
334,common stock,6.232211725313163
335,protocol design,6.231944444444444
336,biocon,6.230440291415901
337,chemoradiation treatment,6.2301974448315915
338,cancer research,6.2276178872649055
339,compensation expense,6.1985214109071975
340,significant estimates,6.188868355535023
341,patent applications,6.177489177489178
342,interim periods,6.173280159521436
343,due accounts,6.161748633879782
344,shares,6.158441558441558
345,net sales,6.158333333333333
346,fair values,6.157142857142857
347,stock option plan,6.15607210626186
348,logistic model,6.143356643356643
349,based immunotherapy,6.124988255247796
350,compensation awards,6.124870617256404
351,expected payment,6.120054945054945
352,cash compensation expense,6.118942307692308
353,motions,6.102941176470589
354,maturity dates,6.095238095238096
355,advaxis constructs,6.085878489326765
356,approval process,6.077759197324415
357,stock,6.067372568332923
358,stock option awards,6.0584997439836155
359,instruments warrants,6.056294326241135
360,early closure,6.053571428571429
361,palliative radiation,6.051054852320675
362,stock set,6.034409527510965
363,generally measured based,5.995444487830275
364,efficacy endpoint,5.983910398544545
365,volatility input,5.974697716077026
366,market price purchases,5.963350109691572
367,advaxis studies,5.960847701149426
368,future payments,5.959811529933481
369,milestone payments,5.958608321377332
370,adxs,5.957277628032345
371,contract research organizations,5.953355704697986
372,1/2 study,5.947349467012389
373,osteosarcoma osteosarcoma,5.945269016697588
374,safety data,5.943958304281132
375,disclosure,5.934555760724868
376,pay advaxis,5.925561029009305
377,existing patents,5.921511126444713
378,efficacy criteria,5.907262277951933
379,statements advaxis,5.90684607136305
380,note agreement,5.8992815694943355
381,axalimogene filolisbac,5.872960372960373
382,enrollment,5.8420523138833005
383,neoepitope sequences,5.833333333333333
384,administrative expenses,5.832640241633654
385,companion dogs,5.821316614420063
386,estimates impact,5.811945278611946
387,credit risk support,5.808782388161163
388,hpv,5.802257382527451
389,study,5.801282051282051
390,conducting gog,5.791666666666667
391,market data,5.760731052984574
392,treatment,5.755182072829132
393,accounting estimates,5.753920587253921
394,continuing risks,5.746929824561404
395,guidance,5.745454545454545
396,lm technology,5.728538154392191
397,equity instruments,5.705899525750102
398,financial statements,5.693899912863353
399,early data,5.687979730233251
400,leases standard,5.676980003149111
401,lung cancer cases,5.674504810413129
402,significant revenue,5.670373126102293
403,results,5.647527910685805
404,neck cancer,5.641731134141001
405,cash amount,5.638392857142857
406,line basis,5.621794871794872
407,sublicense fees,5.595289855072464
408,deferred revenue,5.519270833333334
409,revenue,5.496052003816794
410,payment award,5.48527649490366
411,unjust enrichment,5.473684210526316
412,patients,5.466620225240915
413,investigational immunotherapy,5.455808225455378
414,digit royalties,5.453686246072033
415,radiation treatment,5.451735270379338
416,employee taxes,5.449972360420121
417,llo immunotherapy,5.448966408268734
418,fusion protein,5.416666666666666
419,target cells,5.401659125188537
420,amortization expense,5.36888888888889
421,interim analysis,5.352941176470589
422,treatment option,5.34080624403205
423,final results,5.331269349845201
424,capital resources,5.3
425,fiscal years,5.275038032454361
426,clinical study,5.272134844916371
427,positive osteosarcoma,5.257465240641711
428,modified retrospective,5.25
429,tme,5.177304964539007
430,support payment,5.1754662004662
431,data,5.162551781275891
432,interest rates,5.13974358974359
433,embedded derivative,5.104166666666666
434,full retrospective,5.101190476190476
435,european society,5.090322580645161
436,revenue,5.057816709699146
437,balance sheets,5.050000000000001
438,business plan,5.039362888557892
439,interest income,5.037504783773441
440,secondary endpoints,5.0285714285714285
441,tax credits,5.020833333333334
442,adxs,5.0146369353916525
443,upfront payment,5.0085470085470085
444,symptoms,4.985994397759104
445,stendhal agreement,4.981811942347289
446,clinical program,4.943617021276596
447,repeat cycles,4.94017094017094
448,subsequent events,4.9393939393939394
449,survival rate,4.905915894511761
450,income,4.904904051172708
451,adverse effects,4.904761904761905
452,clinical holds,4.8936170212765955
453,adverse events,4.891774891774892
454,stable disease,4.884669479606188
455,condensed statements,4.876964526268523
456,additional space,4.875824175824176
457,product licensure,4.847490347490347
458,clinical sites,4.822188449848024
459,month survival,4.817391304347826
460,savings account,4.807692307692308
461,dose escalation,4.8076923076923075
462,american society,4.804608294930876
463,american society,4.804608294930876
464,poor outcomes,4.8
465,leased space,4.794871794871796
466,cervical cancer,4.794281524926687
467,balance sheet,4.791666666666667
468,fasb issued asu,4.788935202728306
469,accounting pronouncements,4.783950617283951
470,cytokine release,4.777777777777778
471,administrative organizations,4.764285714285714
472,patent applications,4.74891774891775
473,clinical trials,4.748455730954015
474,current liability,4.738095238095238
475,scholes model,4.737373737373737
476,product candidates,4.731418918918919
477,disclosure claim,4.722488038277512
478,investment securities,4.722222222222222
479,therapeutic improvement,4.714285714285714
480,significant advancement,4.707334785766158
481,employee withholdings,4.703703703703704
482,doubtful accounts,4.7
483,commercial success,4.7
484,net income,4.697761194029851
485,free survival,4.693581780538302
486,cell responses,4.684782608695652
487,compensation,4.6826923076923075
488,logistic model,4.681818181818182
489,increased expression,4.674603174603174
490,footnotes,4.672413793103448
491,unmet medical,4.671328671328672
492,clinical studies,4.669479090242113
493,review process,4.660790598290598
494,axal franchise,4.65639097744361
495,credit losses,4.640564826700899
496,cell response,4.638888888888889
497,significant risks,4.636127355425601
498,palliative radiation,4.633333333333333
499,external collaborations,4.633333333333333
500,volatility input,4.62987012987013
501,compensation,4.627020038784744
502,prostate cancer,4.626941457586619
503,money damages,4.625
504,revenues,4.625
505,key predictors,4.625
506,parker institute,4.625
507,modification accounting,4.617283950617284
508,employee share,4.6106804478897505
509,stock compensation,4.5899503722084365
510,variable interest,4.589743589743589
511,primary objective,4.588292682926829
512,pending investigations,4.583333333333334
513,convertible debt,4.578595317725753
514,interim periods,4.573280159521436
515,basis,4.5717948717948715
516,taxes,4.5697980684811235
517,sponsored trials,4.563172043010753
518,disease progression,4.559883154819864
519,full term,4.556190476190476
520,highly immunogenic,4.555555555555555
521,reporting periods,4.553672316384181
522,lead program,4.55
523,lung cancer,4.541171477079796
524,neoantigens,4.535714285714286
525,clinical oncology,4.532505910165485
526,personalized immunotherapy,4.532299741602067
527,significant cardiac,4.530864197530864
528,stock options,4.5288334069818825
529,fiduciary duty,4.526315789473684
530,license fees,4.523837209302325
531,gynecologic oncology,4.523504273504273
532,infusion,4.519327731092437
533,radiation therapy,4.514285714285714
534,american association,4.514285714285714
535,multiple adjuvants,4.513513513513514
536,multiple pathways,4.513513513513514
537,common cancer,4.511368052856588
538,outstanding warrants,4.508579272477694
539,cash bonus,4.507440476190476
540,partial ruling,4.5
541,dose level,4.5
542,separate units,4.5
543,primary endpoint,4.49906191369606
544,sponsored studies,4.484195402298851
545,previously enrolled,4.481481481481481
546,psa monotherapy portion,4.481324928933383
547,current standard,4.480756686236138
548,collaborative arrangements,4.479166666666666
549,performance obligations,4.470430107526882
550,contractual obligations,4.467096774193548
551,radiation therapies,4.466666666666667
552,clarity,4.466666666666667
553,accounting model,4.465768799102133
554,common stock,4.462980956082394
555,accrued expenses,4.462616822429906
556,office space,4.461538461538462
557,escalation phase,4.453759723422644
558,prior line,4.45
559,clinical trial,4.4499550494456095
560,medical oncology,4.446581196581196
561,amortized cost,4.444444444444445
562,protocol,4.444444444444445
563,cost sharing,4.444444444444445
564,anal cancer,4.439736070381231
565,partial responses,4.434782608695652
566,early closure,4.428571428571429
567,regulatory approval,4.423913043478261
568,complete response,4.417460317460318
569,conversion price,4.415954415954416
570,related disclosure,4.410236822001528
571,date,4.407293127629734
572,initial application,4.4
573,recently published,4.4
574,large payload,4.4
575,technical corrections,4.4
576,related notes,4.39827509951349
577,drug candidates,4.397245762711865
578,clinical benefit,4.3936170212765955
579,potential vaccines,4.38996138996139
580,partial response,4.388888888888889
581,gynecologic malignancies,4.384615384615385
582,annual periods,4.3821036889332
583,financial statements,4.378110439179142
584,potential opportunities,4.375675675675676
585,adjuvant therapy,4.37218045112782
586,drug administration,4.37046004842615
587,cash flows,4.364583333333333
588,existing laws,4.363636363636363
589,treatment regimen,4.361904761904762
590,additional financing,4.36023166023166
591,median follow,4.357142857142858
592,derivative instruments,4.354166666666667
593,license,4.348837209302326
594,debt financings,4.3478260869565215
595,immune system,4.344827586206897
596,revenue,4.342130435189343
597,credit risk,4.339085418464193
598,numerous risks,4.336032388663968
599,tumor microenvironment,4.333333333333334
600,internal capabilities,4.333333333333334
601,lease accounting,4.331569664902998
602,cancer death,4.330645161290322
603,cancer type,4.330645161290322
604,cancer indications,4.330645161290322
605,recurrent/metastatic disease,4.329113924050633
606,rare disease,4.329113924050633
607,disease,4.329113924050633
608,infectious disease,4.329113924050633
609,disease area,4.329113924050633
610,table,4.328571428571428
611,financial condition,4.324675324675325
612,financial guarantees,4.324675324675325
613,investigational sites,4.321428571428571
614,related information,4.319327731092438
615,related disclosures,4.319327731092438
616,phase 1/2,4.312734082397004
617,cash income,4.312344527363184
618,clinical data,4.3091099790230745
619,license agreements,4.308837209302325
620,cancer immunotherapy,4.307389347336834
621,capitalized costs,4.3059163059163055
622,pipeline development,4.299122807017544
623,billed directly,4.285714285714286
624,pathologic effects,4.285714285714286
625,lessor,4.283950617283951
626,stock,4.282258064516129
627,stock,4.282258064516129
628,market price,4.28042328042328
629,period,4.2745098039215685
630,squamous cell,4.274390243902439
631,patent attorney,4.272727272727273
632,employees,4.2727272727272725
633,united states,4.271062271062271
634,market approval,4.2691511387163565
635,single immunotherapy,4.262458471760797
636,pet dogs,4.25974025974026
637,compensation committee,4.258911819887429
638,drug approval,4.258658806190125
639,metastatic squamous,4.258156477668672
640,commercial activities,4.257692307692308
641,axalimogene,4.257575757575758
642,neck cancer,4.257115749525616
643,based compensation,4.25185474424053
644,cell immunity,4.25
645,diluted earnings,4.25
646,earnings,4.25
647,complaint,4.25
648,criteria,4.25
649,foxp3,4.25
650,net book,4.25
651,line journal,4.25
652,exercisable options,4.2465753424657535
653,table,4.245238095238095
654,human papillomavirus,4.241379310344827
655,financial instruments,4.241341991341992
656,financial assets,4.241341991341992
657,significant portion,4.240541616885703
658,related risk,4.237360517977683
659,larger range,4.235294117647059
660,smaller range,4.235294117647059
661,preliminary data,4.23128243143069
662,prices,4.230769230769231
663,measures,4.222222222222222
664,sustained losses,4.219512195121951
665,administrative spending,4.214285714285714
666,ongoing trial,4.212588028169014
667,payments,4.208608321377332
668,promissory note,4.207792207792208
669,proprietary lm,4.204081632653061
670,lead lm,4.204081632653061
671,lm technologytm,4.204081632653061
672,individual lm,4.204081632653061
673,primary osteosarcoma,4.200110864745011
674,prior treatments,4.2
675,development programs,4.199660441426146
676,leases existing,4.196969696969697
677,account balances,4.1923076923076925
678,short period,4.1911764705882355
679,based payments,4.188064875572614
680,derivative complaint,4.1875
681,exit price,4.185185185185185
682,common type,4.1807228915662655
683,common virus,4.1807228915662655
684,cancer,4.180645161290323
685,original maturity,4.178571428571429
686,considered possibly,4.177777777777777
687,administrative expenses,4.176902536715621
688,professional fees,4.175
689,human osteosarcoma,4.173197492163009
690,relationships,4.172413793103448
691,kcm,4.166666666666667
692,successfully escalated,4.166666666666666
693,contingent arrangements,4.166666666666666
694,remaining period,4.163398692810458
695,ind application,4.161111111111111
696,administrative expense,4.160952380952381
697,contractual term,4.16
698,final version,4.157894736842105
699,adjuvant setting,4.157894736842105
700,adjuvant molecule,4.157894736842105
701,remains ongoing,4.15625
702,stock awards,4.155273937532002
703,phase,4.146067415730338
704,start,4.146067415730338
705,squamous carcinoma,4.144390243902439
706,private offerings,4.142857142857142
707,prior period,4.141176470588236
708,court approval,4.1405797101449275
709,llo,4.138888888888889
710,nrg oncology,4.138888888888889
711,oncology,4.138888888888889
712,share prices,4.137745974955277
713,base salary,4.136752136752137
714,product development,4.134708392603129
715,pediatric osteosarcoma,4.131818181818182
716,supply costs,4.1313131313131315
717,escalation cohort,4.129120879120879
718,treated population,4.129032258064516
719,lease term,4.1276190476190475
720,patent licensing,4.124579124579125
721,safety profile,4.124053581828771
722,intangible assets,4.123563218390805
723,net basis,4.121794871794872
724,line basis,4.121794871794872
725,laboratory facilities,4.117647058823529
726,operating activities,4.116515837104072
727,llo immunotherapy,4.115633074935401
728,protocol amendment,4.111111111111112
729,supply chain,4.111111111111111
730,clinical development,4.1094064949608065
731,fighting anal,4.109090909090909
732,investigational lm,4.096938775510203
733,remaining awards,4.095238095238095
734,advantageous market,4.095238095238095
735,market activity,4.095238095238095
736,market exclusivity,4.095238095238095
737,treatment,4.095238095238095
738,market participant,4.095238095238095
739,share price,4.0921619293712315
740,tabular disclosure,4.090909090909091
741,financing,4.088803088803089
742,common share,4.087699635752312
743,based constructs,4.087019579405366
744,greater proportion,4.083333333333334
745,corporate assets,4.083333333333333
746,canine skeleton,4.081632653061225
747,additional steps,4.080952380952381
748,additional countries,4.080952380952381
749,term survivors,4.08
750,exercises,4.079365079365079
751,study protocol,4.07905982905983
752,accompanying notes,4.078947368421053
753,sponsored ind,4.069444444444445
754,american men,4.059740259740259
755,operating purposes,4.0588235294117645
756,data,4.058350100603621
757,activities,4.0576923076923075
758,startup activities,4.0576923076923075
759,increased infiltration,4.055555555555555
760,net loss,4.054878048780488
761,diluted loss,4.054878048780488
762,recorded amounts,4.051299589603283
763,litigation settlement,4.050000000000001
764,office lease,4.0476190476190474
765,revenue,4.044270833333334
766,fiscal periods,4.043868394815553
767,clinical hold,4.043617021276596
768,license agreement,4.040326571004453
769,approach,4.038647342995169
770,ongoing efforts,4.038602941176471
771,primary treatment,4.030197444831591
772,successfully complete,4.0285714285714285
773,clinical study,4.0282324058919805
774,manufacturing capabilities,4.0256410256410255
775,transition approach,4.025575447570333
776,net proceeds,4.0227272727272725
777,expenses,4.021440351841671
778,benefit costs,4.020202020202021
779,facilities costs,4.020202020202021
780,internal costs,4.020202020202021
781,stock,4.019100169779287
782,combination regimen,4.017721518987342
783,escalation portion,4.0173697270471465
784,canine osteosarcoma,4.013450834879406
785,market risk,4.013270882123341
786,update provide,4.012121212121212
787,treatment options,4.008480104370515
788,warrant liability,4.007936507936508
789,cash,4.007440476190476
790,financing activities,4.003638253638254
791,supplemental disclosures,4.0
792,actively engaged,4.0
793,supplies,4.0
794,scale back,4.0
795,necessarily indicative,4.0
796,licensee possessing,4.0
797,dilution protection,4.0
798,dividend yield,4.0
799,practical expedients,4.0
800,unusual items,4.0
801,altogether removing,4.0
802,fundamental transaction,4.0
803,trading day,4.0
804,voluntary election,4.0
805,personal funds,4.0
806,rsu activity,4.0
807,employment inducements,4.0
808,brought derivatively,4.0
809,nominal defendant,4.0
810,injunctive relief,4.0
811,square feet,4.0
812,execution,4.0
813,ensure reliable,4.0
814,orderly transaction,4.0
815,tumor shrinkage,4.0
816,significantly improve,4.0
817,responded readily,4.0
818,profit organization,4.0
819,scchns,4.0
820,mucosal linings,4.0
821,oral cavity,4.0
822,increasing incidence,4.0
823,mount sinai,4.0
824,baylor college,4.0
825,peripheral blood,4.0
826,resection tumor,4.0
827,cigarette smoking,4.0
828,predominately middle,4.0
829,larger breeds,4.0
830,frequently employed,4.0
831,significantly prolong,4.0
832,acvim forum,4.0
833,cardiac toxicity,4.0
834,canine/feline lymphoma,4.0
835,tumor activity,4.0
836,conventional chemotherapeutic,4.0
837,successfully compete,4.0
838,substantial investment,4.0
839,accumulated deficit,4.0
840,information,4.0
841,effort,4.0
842,curative intent,4.0
843,toxicities,4.0
844,temporarily suspended,4.0
845,incidence,4.0
846,detoxified listeriolysin,4.0
847,infectious diseases,4.0
848,myers,4.0
849,rewards,4.0
850,profit sharing,4.0
851,significantly contribute,4.0
852,output,4.0
853,missing elements,4.0
854,predominately reimbursed,4.0
855,discontinuation criterion,4.0
856,baseline scan,4.0
857,fees,3.9985294117647054
858,annual meeting,3.9950980392156863
859,annual meeting,3.9950980392156863
860,human,3.9950024987506243
861,milestone payments,3.9939024390243905
862,standard related,3.990560607804766
863,equity offerings,3.9879275653923543
864,related grade,3.9859943977591037
865,specifically related,3.9859943977591037
866,generally consistent,3.9846153846153847
867,llo,3.982638888888889
868,precision immunotherapy,3.9767441860465116
869,lm technology,3.974914965986394
870,parties,3.9743589743589745
871,court,3.966666666666667
872,funded primarily,3.9642857142857144
873,expenses,3.9626168224299065
874,internal expenses,3.9626168224299065
875,office expenses,3.9626168224299065
876,employment agreements,3.96
877,consulting agreements,3.96
878,maturity investments,3.9598214285714284
879,mortality,3.958333333333333
880,accounting standard,3.9551834939962793
881,full year,3.953463203463204
882,historical experience,3.9523809523809526
883,early adoption,3.9505494505494507
884,increased number,3.9498644986449865
885,depreciation expense,3.9466666666666668
886,expense category,3.9466666666666668
887,expansion phase,3.9460674157303375
888,prospective based,3.9441624365482233
889,hierarchy,3.9441624365482233
890,based strains,3.9441624365482233
891,period,3.9411764705882355
892,2 events,3.9393939393939394
893,advanced disease,3.937809576224546
894,resectable osteosarcoma,3.9318181818181817
895,amended complaint,3.9318181818181817
896,making targeted,3.928571428571429
897,quarterly report,3.92741935483871
898,employees,3.925388337153043
899,credit,3.9210526315789473
900,study closure,3.92032967032967
901,legal costs,3.9202020202020202
902,adjuvant treatment,3.919799498746867
903,ind activities,3.9188034188034186
904,laboratory expansion,3.9176470588235297
905,identical assets,3.916666666666667
906,cell infiltration,3.916666666666667
907,accumulated data,3.915492957746479
908,data,3.915492957746479
909,collaborative licensing,3.914351851851852
910,business combinations,3.913793103448276
911,business combinations,3.913793103448276
912,llo technology,3.9097222222222223
913,share profits,3.9069767441860463
914,united stated,3.905982905982906
915,party costs,3.902554961378491
916,global biopharma,3.9
917,clinical research,3.8969727259745826
918,leases,3.8921568627450975
919,amounts,3.88953488372093
920,preclinical collaborations,3.886206896551724
921,factors,3.88562091503268
922,disease recurrence,3.8846694796061882
923,business plan,3.8843813387423936
924,tnbc franchise,3.8809523809523814
925,corporate offices,3.8809523809523805
926,interim results,3.879256965944273
927,foreseeable future,3.875
928,future,3.875
929,deemed substantive,3.875
930,substantive effort,3.875
931,forfeited awards,3.873015873015873
932,gross basis,3.871794871794872
933,measure fair,3.871428571428572
934,exchange price,3.8693957115009745
935,resulting primarily,3.8675115207373274
936,estimates,3.8667953667953667
937,accounts payable,3.866666666666667
938,investigator assessment,3.8653846153846154
939,cash investing,3.864583333333333
940,cash equivalents,3.864583333333333
941,cash balances,3.864583333333333
942,cisplatin chemotherapy,3.8636363636363633
943,preclinical studies,3.8620689655172415
944,individual grants,3.862068965517241
945,development,3.8618568894145477
946,prior anti,3.8607142857142858
947,enrollment,3.857142857142857
948,individual defendants,3.8529411764705883
949,licensing proposals,3.851851851851852
950,complete cohort,3.8499999999999996
951,program,3.8499999999999996
952,private equity,3.845070422535211
953,costs,3.8437314319667264
954,preliminary results,3.8421052631578947
955,sublicense fees,3.841666666666667
956,annual report,3.8391840607210623
957,cancer research,3.834000865988309
958,payables,3.833333333333333
959,volatility,3.8321428571428573
960,conducted exclusively,3.831168831168831
961,immunologic effects,3.831168831168831
962,table sets,3.8285714285714283
963,legal proceedings,3.8285714285714283
964,annual rent,3.8284313725490193
965,royalty payments,3.8272357723577235
966,hpv,3.825513196480938
967,design,3.8221153846153846
968,periods,3.8203389830508474
969,excellence,3.8181818181818183
970,studies,3.817528735632184
971,based awards,3.8171783095640963
972,equity plan,3.815658657829329
973,hot franchise,3.8142857142857145
974,amortization expense,3.8133333333333335
975,cash expense,3.8112500000000002
976,multiple patients,3.8050495636702535
977,supply agreement,3.8026004728132388
978,extraordinary items,3.8
979,relative fair,3.8
980,valuable insight,3.8
981,expansion phases,3.8
982,target common,3.7961075069508805
983,customer contracts,3.7941176470588234
984,commercial milestones,3.7862068965517244
985,company,3.7851145038167937
986,investments,3.78125
987,2 study,3.780682800345722
988,study,3.780682800345722
989,study,3.780682800345722
990,considered remote,3.7777777777777777
991,entity,3.7777777777777777
992,unconsolidated entity,3.7777777777777777
993,protocol analysis,3.7777777777777777
994,advanced therapies,3.7753623188405796
995,development activities,3.773481781376518
996,executive employees,3.7727272727272725
997,gross proceeds,3.7727272727272725
998,collaboration agreements,3.7725
999,collaboration agreements,3.7725
1000,platform technology,3.770833333333333
1001,licensed technology,3.770833333333333
1002,proprietary technology,3.770833333333333
1003,provisions,3.769230769230769
1004,recently issued,3.769230769230769
1005,dilution provisions,3.769230769230769
1006,amounts,3.7691645133505594
1007,cash,3.767809139784946
1008,transition relief,3.764705882352941
1009,transition methods,3.764705882352941
1010,symptomatic treatment,3.761904761904762
1011,neoadjuvant treatment,3.761904761904762
1012,9 cfu,3.76
1013,9 cfu,3.76
1014,1x109 cfu,3.76
1015,5x109 cfu,3.76
1016,waste claims,3.75
1017,state nols,3.75
1018,regulatory registration,3.75
1019,inactive agents,3.75
1020,cmc information,3.75
1021,determined basis,3.746794871794872
1022,dilutive options,3.7465753424657535
1023,hpv e7,3.745967741935484
1024,cancers,3.74483306836248
1025,delaware court,3.7444444444444445
1026,party grants,3.744421906693712
1027,final milestones,3.7441016333938295
1028,proceeds,3.737433155080214
1029,future grants,3.737068965517241
1030,development costs,3.735991493886231
1031,initial study,3.7346153846153847
1032,authoritative guidance,3.7333333333333334
1033,guidance,3.7333333333333334
1034,guidance,3.7333333333333334
1035,immunotherapy agents,3.7267441860465116
1036,high dose,3.7222222222222223
1037,significant increase,3.721947000078635
1038,extended based,3.721940214326001
1039,losses,3.7195121951219514
1040,study drug,3.719361147327249
1041,extended period,3.718954248366013
1042,equity awards,3.7180862955510845
1043,company stock,3.717372568332923
1044,development arm,3.7157894736842105
1045,development initiatives,3.7157894736842105
1046,amgen,3.7146765683017398
1047,lease amendment,3.7142857142857144
1048,active markets,3.7142857142857144
1049,support payments,3.71359940872136
1050,related cancers,3.711219622984329
1051,revenue,3.7109375
1052,major components,3.7058823529411766
1053,major sources,3.7058823529411766
1054,additional patients,3.705821764442454
1055,contractual terms,3.705
1056,court,3.7035087719298243
1057,immunologic adjuvant,3.7033492822966507
1058,initially diagnosed,3.7017045454545454
1059,increased headcount,3.701388888888889
1060,support payment,3.7004662004662006
1061,reasonable expectation,3.6956521739130435
1062,market participants,3.6952380952380954
1063,ind meeting,3.6944444444444446
1064,manufacturing,3.6923076923076925
1065,oral agreement,3.6914893617021276
1066,alleged agreement,3.6914893617021276
1067,tentative agreement,3.6914893617021276
1068,final results,3.6842105263157894
1069,purchases,3.6829268292682924
1070,development expenses,3.678406296114117
1071,potential inclusion,3.6756756756756754
1072,shows potential,3.6756756756756754
1073,material impact,3.675
1074,standard amends,3.671232876712329
1075,standard significantly,3.671232876712329
1076,aratana therapeutics,3.666666666666667
1077,aratana,3.666666666666667
1078,contingent assets,3.666666666666667
1079,similar assets,3.666666666666667
1080,grade,3.666666666666667
1081,systemic toxicities,3.666666666666667
1082,enables aratana,3.666666666666667
1083,development expense,3.6624561403508773
1084,anti pd,3.6607142857142856
1085,services,3.6600985221674875
1086,ongoing research,3.6596057046979866
1087,company measures,3.6573367260390164
1088,fair values,3.6571428571428575
1089,commenced enrollment,3.6571428571428575
1090,earnings process,3.6538461538461537
1091,predetermined safety,3.653465346534653
1092,considered substantive,3.6527777777777777
1093,repeat doses,3.651282051282051
1094,proposed asu 2015,3.6482758620689655
1095,proposed asu 2016,3.6482758620689655
1096,normal cells,3.647619047619048
1097,management,3.640498899486427
1098,cash proceeds,3.637310606060606
1099,tumor types,3.6363636363636367
1100,income statement,3.6352611940298507
1101,company,3.6351145038167942
1102,liability warrants,3.6306990881458967
1103,544 deaths,3.6296296296296298
1104,terms,3.625
1105,independent international,3.625
1106,expansion cohort,3.6214285714285714
1107,costs,3.6202020202020204
1108,cash,3.6182065217391304
1109,1 patient,3.616806722689075
1110,patient,3.616806722689075
1111,sufficient understanding,3.6153846153846154
1112,expense,3.6133333333333333
1113,preliminary findings,3.609907120743034
1114,brown university,3.608695652173913
1115,metastatic hpv,3.604733975701717
1116,developing lm,3.604081632653061
1117,lung cancers,3.6024182076813656
1118,information,3.6
1119,equipment,3.6
1120,adequate follow,3.6
1121,osteosarcoma,3.5984848484848486
1122,development efforts,3.598142414860681
1123,effective beginning,3.5973214285714286
1124,principal market,3.5952380952380953
1125,integral part,3.5945945945945947
1126,global agreement,3.5914893617021275
1127,future development,3.5907894736842105
1128,patient recruitment,3.5882352941176467
1129,individual patient,3.5882352941176467
1130,patient population,3.5882352941176467
1131,instruments,3.5833333333333335
1132,difference estimates,3.581081081081081
1133,term follow,3.58
1134,stage studies,3.5797836375929686
1135,development grants,3.577858439201452
1136,tumors,3.571428571428571
1137,solid tumors,3.571428571428571
1138,active enrollment,3.571428571428571
1139,action,3.5666666666666664
1140,combination phase,3.563788934717679
1141,change materially,3.5555555555555554
1142,investigational anti,3.553571428571429
1143,equity warrants,3.5471980821096794
1144,collaboration guidance,3.5458333333333334
1145,aged dogs,3.5454545454545454
1146,update clarify,3.5454545454545454
1147,franchise,3.541208791208791
1148,partially offset,3.5357142857142856
1149,systemic chemotherapy,3.5303030303030303
1150,seer database,3.5294117647058822
1151,substantive process,3.5288461538461537
1152,equity purchases,3.527997251803504
1153,considered observable,3.5277777777777777
1154,proceeds,3.52635046113307
1155,actual results,3.526315789473684
1156,results,3.526315789473684
1157,contract terms,3.525
1158,unspecified amount,3.5238095238095237
1159,actual amount,3.5238095238095237
1160,collaborative arrangement,3.520833333333333
1161,services,3.5172413793103448
1162,professional services,3.5172413793103448
1163,mutations,3.5166666666666666
1164,bono action,3.5153846153846153
1165,common shareholders,3.5140562248995986
1166,award,3.510344827586207
1167,study,3.5096153846153846
1168,collaboration agreement,3.5039893617021276
1169,preclinical data,3.501699854298203
1170,reviewed individually,3.5
1171,differ materially,3.5
1172,face interaction,3.5
1173,amputation,3.5
1174,amputation,3.5
1175,mason,3.5
1176,low double,3.5
1177,principal participant,3.5
1178,material amount,3.498809523809524
1179,accounting estimate,3.4982363315696645
1180,biocon,3.496363636363636
1181,4 biocon,3.496363636363636
1182,positive outcome,3.4926470588235294
1183,stage design,3.491421568627451
1184,final analysis,3.4912280701754383
1185,efficacy population,3.484848484848485
1186,aggregate intrinsic,3.482222222222222
1187,services,3.4819472616632856
1188,action,3.4714285714285715
1189,breaker presentation,3.4705882352941178
1190,management,3.4680851063829787
1191,alive greater,3.467948717948718
1192,court,3.466666666666667
1193,cancer cases,3.463978494623656
1194,arrangement qualifies,3.458333333333333
1195,common shares,3.453450164293538
1196,evaluate progression,3.452991452991453
1197,part defendants,3.4475357710651826
1198,annual increases,3.447478991596639
1199,patient enrollment,3.4453781512605044
1200,pennsylvania school,3.4444444444444446
1201,biocon,3.444055944055944
1202,end results,3.442982456140351
1203,metastatic her2,3.4417662337662334
1204,unknown factors,3.4411764705882355
1205,company,3.435114503816794
1206,company reviews,3.435114503816794
1207,company,3.435114503816794
1208,company,3.435114503816794
1209,company,3.435114503816794
1210,company,3.435114503816794
1211,company,3.435114503816794
1212,company,3.435114503816794
1213,company,3.435114503816794
1214,company,3.435114503816794
1215,company,3.435114503816794
1216,company,3.435114503816794
1217,company,3.435114503816794
1218,amounts,3.434616850934045
1219,expansion study,3.434615384615385
1220,tumor cells,3.4333333333333336
1221,dendritic cells,3.4333333333333336
1222,cancerous cells,3.4333333333333336
1223,active development,3.4300751879699245
1224,3 treatment,3.428571428571429
1225,development revenue,3.4267269736842105
1226,based year,3.4214351638209504
1227,109 patients,3.420568308221256
1228,26 patients,3.420568308221256
1229,treated patients,3.420568308221256
1230,persuasive evidence,3.416666666666667
1231,successfully manufacture,3.416666666666667
1232,expected period,3.416176470588235
1233,ongoing investigator,3.40625
1234,incurred loss,3.404878048780488
1235,granted aratana,3.4035087719298245
1236,march 2015 stating,3.4
1237,2016 issue,3.4
1238,evaluable pts,3.4
1239,company,3.399820386169735
1240,vested rsus,3.3959276018099547
1241,contractual commitments,3.3957894736842107
1242,amgen,3.395348837209302
1243,based calculation,3.394162436548223
1244,successfully completed,3.389830508474576
1245,completed allowing,3.389830508474576
1246,dna sequencing,3.388888888888889
1247,traes,3.380952380952381
1248,traes,3.380952380952381
1249,adjuvant axal,3.378947368421053
1250,continues conducting,3.375
1251,times,3.375
1252,oral late,3.375
1253,major families,3.372549019607843
1254,trae,3.3666666666666667
1255,3 trae,3.3666666666666667
1256,established based,3.36082910321489
1257,limited availability,3.3600000000000003
1258,results,3.3596491228070176
1259,risk factors,3.359209257473481
1260,patient treatment,3.3501400560224086
1261,commercialization partner,3.3499999999999996
1262,company,3.346879209699147
1263,presentation basis,3.3423831070889896
1264,record allowances,3.333333333333333
1265,safety report,3.330884701373363
1266,hpv worldwide,3.329301075268817
1267,works,3.3269230769230766
1268,neo totaling $4,3.3269230769230766
1269,her2,3.325647058823529
1270,fda notified,3.325581395348837
1271,recognized revenues,3.321078431372549
1272,observed treatment,3.3207282913165264
1273,patients,3.3201074787281684
1274,24 patients,3.3201074787281684
1275,neck cancers,3.318362480127186
1276,research collaboration,3.3158557046979866
1277,royalties,3.31082910321489
1278,licensing arrangement,3.310185185185185
1279,company,3.310114503816794
1280,positive head,3.3088235294117645
1281,fiscal years,3.3062880324543613
1282,immunotherapy,3.3036672629695882
1283,development milestones,3.3019963702359347
1284,fiscal year,3.300802139037433
1285,phase,3.299913569576491
1286,greater immunogenicity,3.2976190476190474
1287,704 reported aes,3.2962962962962963
1288,reduce overhead,3.2941176470588234
1289,previous findings,3.2941176470588234
1290,time,3.291666666666667
1291,patients,3.29153605015674
1292,3/6 patients,3.29153605015674
1293,accruing patients,3.29153605015674
1294,15 patients,3.29153605015674
1295,fda,3.290287277701778
1296,ind filing,3.2896825396825395
1297,aggregate amount,3.2838095238095235
1298,assumptions,3.2835249042145596
1299,study,3.2816742081447963
1300,loss,3.279878048780488
1301,amount,3.2738095238095237
1302,time employees,3.2727272727272725
1303,company,3.268447837150127
1304,young women,3.2682926829268295
1305,indian women,3.2682926829268295
1306,moderate grade,3.2666666666666666
1307,market access,3.261904761904762
1308,company,3.2586439155814997
1309,effective date,3.257603686635945
1310,patients,3.256241932509681
1311,estimated impact,3.2555555555555555
1312,productive pre,3.25
1313,unconsolidated entities,3.25
1314,implementation guidance,3.2333333333333334
1315,development services,3.2330308529945553
1316,part study,3.229209979209979
1317,preclinical study,3.220822281167109
1318,pay $10 million,3.22008547008547
1319,company,3.2128922815945717
1320,care treatment,3.211904761904762
1321,revenue recognition,3.2109375
1322,specific amendments,3.2105263157894735
1323,research,3.209238057639163
1324,receptors,3.208
1325,equipment property,3.2
1326,2016 issue,3.2
1327,increase significantly,3.1910828025477707
1328,modest increase,3.1910828025477707
1329,coverage,3.1910828025477707
1330,jersey,3.185897435897436
1331,committee,3.1819887429643527
1332,study,3.18006993006993
1333,combination treatment,3.1796262808921036
1334,equity section,3.1784037558685445
1335,expenses,3.1706168224299063
1336,milestone event,3.166666666666667
1337,ultimately vest,3.166666666666667
1338,unusual nature,3.166666666666667
1339,kcm,3.166666666666667
1340,heterogeneous nature,3.166666666666667
1341,replace today,3.166666666666667
1342,sellas,3.166666666666667
1343,circumstances,3.166666666666667
1344,enrollment,3.1610644257703084
1345,stimulate anti,3.1607142857142856
1346,gaap involves,3.16
1347,liabilities,3.15625
1348,percent improvement,3.1538461538461537
1349,inherently subject,3.1515151515151514
1350,management purchases,3.1510119356512716
1351,high risk,3.1402550091074684
1352,differ substantially,3.125
1353,months,3.11864406779661
1354,twelve months,3.11864406779661
1355,neck,3.1176470588235294
1356,employees,3.1166989039329467
1357,primarily attributable,3.1124338624338623
1358,date,3.1072931276297338
1359,royalty amount,3.1071428571428568
1360,neo construct,3.1047008547008543
1361,defendants,3.1029411764705883
1362,recognize revenue,3.0955528846153846
1363,amgen agreement,3.0868381989114297
1364,4 event,3.0833333333333335
1365,shares,3.0804195804195804
1366,stendhal agreement,3.078586135895676
1367,unique mutations,3.0666666666666664
1368,company,3.0647441334464234
1369,inception,3.0618094953717527
1370,fixed number,3.0609756097560976
1371,small number,3.0609756097560976
1372,measurement date,3.057603686635945
1373,cash increase,3.055666135881104
1374,remains open,3.052631578947368
1375,company,3.050499119201409
1376,shares,3.0419580419580416
1377,12 shares,3.0419580419580416
1378,hpv infection,3.0376344086021505
1379,company,3.0161955848978748
1380,spot target,3.0153846153846153
1381,company,3.0140618722378463
1382,4 million resulting,3.012200165425972
1383,2 million resulting,3.012200165425972
1384,chancery,2.9914529914529915
1385,mine collaboration,2.979166666666667
1386,total fair,2.97741935483871
1387,scope improvements,2.962121212121212
1388,tnbc patients,2.958202716823407
1389,potential shares,2.9484029484029484
1390,adopting asu 2016,2.9482758620689653
1391,study,2.9423076923076925
1392,stage study,2.938536953242836
1393,study patients,2.9261514347721245
1394,patient surveillance,2.9215686274509802
1395,patients,2.9211656797863697
1396,aggregate consideration,2.92
1397,planned investigation,2.916666666666667
1398,commercialization agreement,2.9081560283687944
1399,contingent liabilities,2.90625
1400,hot products,2.8962962962962964
1401,safety,2.8756875687568755
1402,target neoepitopes,2.8653846153846154
1403,adxs,2.858071278825996
1404,operations,2.85334695963209
1405,axal,2.850682261208577
1406,placebo,2.841666666666667
1407,company,2.8351145038167935
1408,controlled study,2.8346153846153843
1409,total approximately 3,2.832400904654208
1410,company,2.82494501229137
1411,lts,2.8231382978723403
1412,higher,2.813953488372093
1413,increase,2.806467417932386
1414,commercialization milestones,2.802873563218391
1415,conducted gog,2.7954545454545454
1416,study,2.7774725274725274
1417,veterinary medicine,2.7666666666666666
1418,taxes,2.746268656716418
1419,occurrence,2.7142857142857144
1420,raised approximately $221,2.7004360952700432
1421,order,2.6923076923076925
1422,axal support,2.6907496012759173
1423,rate,2.6885245901639343
1424,company,2.685114503816794
1425,company,2.685114503816794
1426,company,2.685114503816794
1427,her2,2.6746666666666665
1428,company,2.655702739110912
1429,levels,2.6551724137931036
1430,recurrent,2.652173913043478
1431,operations advaxis,2.64524048655284
1432,unobservable inputs,2.6363636363636367
1433,gog foundation,2.607142857142857
1434,month,2.6
1435,gaap accepted,2.5980952380952385
1436,2 patients,2.5954576187841907
1437,rights,2.5384615384615383
1438,entities,2.5357142857142856
1439,significant,2.5308641975308643
1440,parties,2.5282805429864252
1441,axal due,2.5161345987920622
1442,amgen,2.5006119951040393
1443,knoll,2.5
1444,dose,2.5
1445,burden,2.5
1446,initiate company,2.499630632849052
1447,fair statement,2.4875
1448,programs,2.4838709677419355
1449,free,2.4761904761904763
1450,provide,2.466666666666667
1451,cervical,2.463636363636364
1452,earned,2.4571428571428573
1453,settlement,2.45
1454,cost,2.4444444444444446
1455,patients,2.4343931930138827
1456,president,2.4285714285714284
1457,licensure,2.4285714285714284
1458,address,2.4285714285714284
1459,probable,2.4285714285714284
1460,pursuant,2.4285714285714284
1461,product,2.418918918918919
1462,arrangements,2.4166666666666665
1463,additional 164,2.414285714285714
1464,clinical,2.393617021276596
1465,develop neo,2.3935897435897435
1466,response,2.388888888888889
1467,increased,2.388888888888889
1468,obligations,2.3870967741935485
1469,generally,2.3846153846153846
1470,million women,2.377267041901188
1471,existing,2.3636363636363638
1472,license,2.3488372093023258
1473,deferred,2.3333333333333335
1474,cancer,2.3306451612903225
1475,disease,2.329113924050633
1476,objective,2.32
1477,related,2.319327731092437
1478,compensation,2.3076923076923075
1479,application,2.3
1480,prostate,2.2962962962962963
1481,society,2.2903225806451615
1482,make,2.2857142857142856
1483,directly,2.2857142857142856
1484,effects,2.2857142857142856
1485,accounting,2.2839506172839505
1486,stock,2.282258064516129
1487,developed adxs,2.2787061994609163
1488,events,2.272727272727273
1489,input,2.272727272727273
1490,failed,2.272727272727273
1491,primary,2.268292682926829
1492,approach,2.260869565217391
1493,criteria,2.25
1494,short,2.25
1495,claims,2.25
1496,regulatory,2.25
1497,achieve,2.25
1498,000 options,2.2465753424657535
1499,952 options,2.2465753424657535
1500,payments,2.2439024390243905
1501,human,2.2413793103448274
1502,metastatic,2.2337662337662336
1503,payment,2.230769230769231
1504,conversion,2.230769230769231
1505,progression,2.230769230769231
1506,exclusive,2.230769230769231
1507,losses,2.2195121951219514
1508,survival,2.217391304347826
1509,therapy,2.2142857142857144
1510,normal,2.2142857142857144
1511,1 therapy,2.2142857142857144
1512,accounts,2.2
1513,infusion,2.2
1514,prior,2.2
1515,chemoradiation,2.2
1516,minimum,2.2
1517,mild,2.2
1518,account,2.1923076923076925
1519,price,2.185185185185185
1520,model,2.1818181818181817
1521,common,2.180722891566265
1522,advancement,2.176470588235294
1523,fees,2.175
1524,approval,2.1739130434782608
1525,requires,2.1724137931034484
1526,required,2.1724137931034484
1527,executive,2.1666666666666665
1528,testing,2.1666666666666665
1529,ongoing,2.15625
1530,constructs,2.142857142857143
1531,provided,2.142857142857143
1532,obtain,2.142857142857143
1533,digit,2.142857142857143
1534,amounts,2.13953488372093
1535,llo,2.138888888888889
1536,biocon,2.1363636363636362
1537,partner,2.1333333333333333
1538,treated,2.129032258064516
1539,revenues,2.125
1540,carcinoma,2.12
1541,laboratory,2.1176470588235294
1542,black,2.111111111111111
1543,pay,2.111111111111111
1544,anal,2.109090909090909
1545,adequate,2.1
1546,market,2.0952380952380953
1547,disclosure,2.090909090909091
1548,drug,2.0847457627118646
1549,performance,2.0833333333333335
1550,term,2.08
1551,notes,2.0789473684210527
1552,include,2.076923076923077
1553,exercise,2.066666666666667
1554,trial,2.056338028169014
1555,statements,2.053435114503817
1556,lease,2.0476190476190474
1557,experienced,2.0285714285714285
1558,complete,2.0285714285714285
1559,squamous,2.024390243902439
1560,costs,2.0202020202020203
1561,tumor,2.0
1562,funded,2.0
1563,antigen,2.0
1564,specific,2.0
1565,information,2.0
1566,technologies,2.0
1567,effect,2.0
1568,denied,2.0
1569,complaints,2.0
1570,markets,2.0
1571,level,2.0
1572,level,2.0
1573,level,2.0
1574,successfully,2.0
1575,caused,2.0
1576,cytotoxic,2.0
1577,virus,2.0
1578,spending,2.0
1579,immunotherapy,1.9767441860465116
1580,material,1.975
1581,plan,1.9705882352941178
1582,beginning,1.96875
1583,court,1.9666666666666666
1584,received,1.964705882352941
1585,primarily,1.9642857142857142
1586,expenses,1.9626168224299065
1587,agreements,1.96
1588,worldwide,1.9583333333333333
1589,committee,1.951219512195122
1590,sales,1.95
1591,expense,1.9466666666666668
1592,financing,1.945945945945946
1593,based,1.9441624365482233
1594,period,1.9411764705882353
1595,purchase 122,1.9411764705882353
1596,purchase,1.9411764705882353
1597,purchase,1.9411764705882353
1598,osteosarcoma,1.9318181818181819
1599,liability,1.9285714285714286
1600,proceedings,1.9285714285714286
1601,targeted,1.9285714285714286
1602,neck,1.9264705882352942
1603,risk,1.9180327868852458
1604,end,1.9166666666666667
1605,assets,1.9166666666666667
1606,instruments,1.9166666666666667
1607,data,1.9154929577464788
1608,business,1.9137931034482758
1609,recorded,1.911764705882353
1610,contained,1.9090909090909092
1611,share,1.9069767441860466
1612,option,1.903225806451613
1613,000 resulting,1.903225806451613
1614,resulting,1.903225806451613
1615,contract,1.9
1616,legal,1.9
1617,global,1.9
1618,action,1.9
1619,investigational,1.8928571428571428
1620,tolerated,1.8888888888888888
1621,critical,1.8888888888888888
1622,impairment,1.8888888888888888
1623,efforts,1.8823529411764706
1624,party,1.8823529411764706
1625,substantive,1.875
1626,future,1.875
1627,determined,1.875
1628,awards,1.873015873015873
1629,basis,1.8717948717948718
1630,amortization,1.8666666666666667
1631,cash,1.8645833333333333
1632,chemotherapy,1.8636363636363635
1633,grants,1.8620689655172413
1634,ind,1.8611111111111112
1635,enrollment,1.8571428571428572
1636,defendants,1.8529411764705883
1637,licensing,1.8518518518518519
1638,found,1.85
1639,equity,1.8450704225352113
1640,immunotherapies,1.84375
1641,receive,1.8409090909090908
1642,leases,1.8333333333333333
1643,meeting,1.8333333333333333
1644,continues,1.8333333333333333
1645,table,1.8285714285714285
1646,fiscal 2015,1.8235294117647058
1647,paid,1.8235294117647058
1648,paid $50,1.8235294117647058
1649,fiscal 2019,1.8235294117647058
1650,cohort,1.8214285714285714
1651,cohort,1.8214285714285714
1652,cohort,1.8214285714285714
1653,excellence,1.8181818181818181
1654,collaboration,1.8125
1655,adoption,1.8076923076923077
1656,vested,1.8076923076923077
1657,loss,1.8048780487804879
1658,extraordinary,1.8
1659,prevent,1.8
1660,expansion,1.8
1661,commenced,1.8
1662,quality,1.7857142857142858
1663,investments,1.78125
1664,delaware,1.7777777777777777
1665,extended,1.7777777777777777
1666,stated,1.7777777777777777
1667,considered,1.7777777777777777
1668,construct,1.7777777777777777
1669,entity,1.7777777777777777
1670,proceeds,1.7727272727272727
1671,technology,1.7708333333333333
1672,issued,1.7692307692307692
1673,accounted,1.7692307692307692
1674,provisions,1.7692307692307692
1675,seer,1.7647058823529411
1676,database,1.7647058823529411
1677,transition,1.7647058823529411
1678,treatment,1.7619047619047619
1679,aggregate,1.76
1680,9 cfu,1.76
1681,cfu,1.76
1682,including,1.7536231884057971
1683,carrying,1.75
1684,complaint,1.75
1685,state,1.75
1686,observable,1.75
1687,contingent,1.75
1688,agents,1.75
1689,milestone,1.75
1690,granted,1.736842105263158
1691,representing,1.736842105263158
1692,guidance,1.7333333333333334
1693,intrinsic,1.7222222222222223
1694,commercialize,1.7222222222222223
1695,development,1.7157894736842105
1696,offices,1.7142857142857142
1697,active,1.7142857142857142
1698,traes,1.7142857142857142
1699,revenue,1.7109375
1700,2015 revenue,1.7109375
1701,2016 revenue,1.7109375
1702,portion,1.7096774193548387
1703,major,1.7058823529411764
1704,initiated,1.7058823529411764
1705,warrants,1.702127659574468
1706,impact,1.7
1707,trae,1.7
1708,reasonable,1.6956521739130435
1709,manufacturing,1.6923076923076923
1710,agreement,1.6914893617021276
1711,exchange,1.6842105263157894
1712,purchases,1.6829268292682926
1713,total 3,1.6774193548387097
1714,total,1.6774193548387097
1715,report,1.6774193548387097
1716,potential,1.6756756756756757
1717,standard,1.6712328767123288
1718,aratana,1.6666666666666667
1719,time,1.6666666666666667
1720,measured,1.6666666666666667
1721,pursue,1.6666666666666667
1722,dates,1.6666666666666667
1723,kcm,1.6666666666666667
1724,amendment,1.6666666666666667
1725,rent,1.6666666666666667
1726,countries,1.6666666666666667
1727,grade,1.6666666666666667
1728,steps,1.6666666666666667
1729,grade,1.6666666666666667
1730,includes,1.6666666666666667
1731,tme,1.6666666666666667
1732,infiltration,1.6666666666666667
1733,infection,1.6666666666666667
1734,planned,1.6666666666666667
1735,1 antibody,1.6666666666666667
1736,systemic,1.6666666666666667
1737,sublicense,1.6666666666666667
1738,tnbc,1.6666666666666667
1739,mutations,1.6666666666666667
1740,suggest,1.6666666666666667
1741,payable,1.6666666666666667
1742,experience,1.6666666666666667
1743,larkin,1.6666666666666667
1744,continuing,1.6666666666666667
1745,vest,1.6666666666666667
1746,replace,1.6666666666666667
1747,specifically,1.6666666666666667
1748,aes,1.6666666666666667
1749,anti,1.6607142857142858
1750,general,1.6557377049180328
1751,process,1.6538461538461537
1752,safety,1.6534653465346534
1753,hold,1.65
1754,showed,1.6470588235294117
1755,types,1.6363636363636365
1756,study,1.6346153846153846
1757,0265 study,1.6346153846153846
1758,reported,1.6296296296296295
1759,enrolled,1.6296296296296295
1760,date,1.6290322580645162
1761,effective,1.6285714285714286
1762,announced,1.625
1763,terms,1.625
1764,independent,1.625
1765,substantially,1.625
1766,involved,1.625
1767,target,1.6153846153846154
1768,sufficient,1.6153846153846154
1769,believes,1.6153846153846154
1770,resulted,1.6153846153846154
1771,bono,1.6153846153846154
1772,university,1.608695652173913
1773,advanced,1.608695652173913
1774,employees,1.606060606060606
1775,property,1.6
1776,presented,1.6
1777,consistent,1.6
1778,incurred,1.6
1779,equipment,1.6
1780,hot,1.6
1781,participants,1.6
1782,litigation,1.6
1783,moderate,1.6
1784,part,1.5945945945945945
1785,rsus,1.588235294117647
1786,patient,1.588235294117647
1787,preclinical,1.5862068965517242
1788,milestones,1.5862068965517242
1789,royalty,1.5833333333333333
1790,estimates,1.5810810810810811
1791,plans,1.5789473684210527
1792,fasb,1.5714285714285714
1793,vigorously,1.5714285714285714
1794,set,1.5714285714285714
1795,tumors,1.5714285714285714
1796,note,1.5714285714285714
1797,note 9,1.5714285714285714
1798,review,1.5625
1799,number,1.5609756097560976
1800,observed,1.5588235294117647
1801,estimated,1.5555555555555556
1802,recurrence,1.5555555555555556
1803,change,1.5555555555555556
1804,update,1.5454545454545454
1805,improvements,1.5454545454545454
1806,immunologic,1.5454545454545454
1807,conducted,1.5454545454545454
1808,men,1.5454545454545454
1809,dogs,1.5454545454545454
1810,000 dogs,1.5454545454545454
1811,raised,1.5454545454545454
1812,achieved,1.5454545454545454
1813,achieved 24,1.5454545454545454
1814,conducting,1.5416666666666667
1815,offset,1.5357142857142858
1816,1 advaxis,1.528735632183908
1817,2 advaxis,1.528735632183908
1818,4 advaxis,1.528735632183908
1819,advaxis,1.528735632183908
1820,results,1.5263157894736843
1821,8 results,1.5263157894736843
1822,9 results,1.5263157894736843
1823,amount,1.5238095238095237
1824,services,1.5172413793103448
1825,included,1.5106382978723405
1826,research,1.5033557046979866
1827,stimulate,1.5
1828,breast,1.5
1829,fixed,1.5
1830,differ,1.5
1831,purchased,1.5
1832,dilutive,1.5
1833,granting,1.5
1834,recognition,1.5
1835,implementation,1.5
1836,adopting,1.5
1837,served,1.5
1838,waste,1.5
1839,dismissed,1.5
1840,individually,1.5
1841,principal,1.5
1842,unobservable,1.5
1843,face,1.5
1844,small,1.5
1845,veterinary,1.5
1846,amputation,1.5
1847,follow,1.5
1848,mason,1.5
1849,expect,1.5
1850,today,1.5
1851,identified,1.5
1852,straight,1.5
1853,registration,1.5
1854,double,1.5
1855,performed,1.5
1856,ultimately,1.5
1857,efficacy,1.4848484848484849
1858,years,1.4827586206896552
1859,monotherapy,1.4827586206896552
1860,2 years,1.4827586206896552
1861,grant,1.4782608695652173
1862,year,1.4772727272727273
1863,expected,1.475
1864,expected 12,1.475
1865,presentation,1.4705882352941178
1866,support,1.4696969696969697
1867,management,1.4680851063829787
1868,administered,1.4666666666666666
1869,needed,1.4615384615384615
1870,defined,1.4615384615384615
1871,arrangement,1.4583333333333333
1872,care,1.45
1873,calculation,1.45
1874,asu,1.4482758620689655
1875,pennsylvania,1.4444444444444444
1876,maa,1.4444444444444444
1877,base,1.4444444444444444
1878,factors,1.4411764705882353
1879,company,1.4351145038167938
1880,cells,1.4333333333333333
1881,abandoned,1.4285714285714286
1882,filing,1.4285714285714286
1883,anticipate,1.4285714285714286
1884,measurement,1.4285714285714286
1885,combination,1.4177215189873418
1886,event,1.4166666666666667
1887,jersey,1.4166666666666667
1888,jersey,1.4166666666666667
1889,established,1.4166666666666667
1890,evidence,1.4166666666666667
1891,manufacture,1.4166666666666667
1892,scope,1.4166666666666667
1893,developing,1.4
1894,march,1.4
1895,march 22,1.4
1896,evaluable,1.4
1897,annually,1.4
1898,march 19,1.4
1899,sale,1.4
1900,construction,1.4
1901,cat,1.4
1902,agreed,1.4
1903,march 14,1.4
1904,unique,1.4
1905,spot,1.4
1906,amgen,1.3953488372093024
1907,cancers,1.3918918918918919
1908,completed,1.3898305084745763
1909,dna,1.3888888888888888
1910,stendhal,1.3870967741935485
1911,recognize,1.3846153846153846
1912,alive,1.3846153846153846
1913,scchn,1.3846153846153846
1914,excluded,1.375
1915,outcome,1.375
1916,placebo,1.375
1917,late,1.375
1918,hpv,1.3709677419354838
1919,royalties,1.3666666666666667
1920,gaap,1.36
1921,limited,1.36
1922,foundation,1.3571428571428572
1923,bsm,1.3448275862068966
1924,neoepitope,1.3333333333333333
1925,shareholders,1.3333333333333333
1926,section,1.3333333333333333
1927,analysis,1.3333333333333333
1928,designed,1.3333333333333333
1929,surveillance,1.3333333333333333
1930,record,1.3333333333333333
1931,strategic,1.3333333333333333
1932,neo,1.3269230769230769
1933,fda,1.3255813953488371
1934,patents,1.3225806451612903
1935,unaudited,1.3157894736842106
1936,commitments,1.3157894736842106
1937,lts,1.3125
1938,headcount,1.3125
1939,award,1.3103448275862069
1940,met,1.3076923076923077
1941,parties,1.3076923076923077
1942,stage,1.303921568627451
1943,stage,1.303921568627451
1944,stage,1.303921568627451
1945,fair,1.3
1946,entitled,1.3
1947,products,1.2962962962962963
1948,due,1.2950819672131149
1949,000 due,1.2950819672131149
1950,874 due,1.2950819672131149
1951,340 due,1.2950819672131149
1952,214 due,1.2950819672131149
1953,156 due,1.2950819672131149
1954,contracts,1.2941176470588236
1955,reduce,1.2941176470588236
1956,findings,1.2941176470588236
1957,110 patients,1.29153605015674
1958,patients,1.29153605015674
1959,124 patients,1.29153605015674
1960,20 patients,1.29153605015674
1961,90 patients,1.29153605015674
1962,24 patients,1.29153605015674
1963,11 patients,1.29153605015674
1964,9 patients,1.29153605015674
1965,36 patients,1.29153605015674
1966,psa,1.288888888888889
1967,assist,1.2857142857142858
1968,increases,1.2857142857142858
1969,stages,1.2857142857142858
1970,evaluating,1.2758620689655173
1971,shares,1.2727272727272727
1972,481 shares,1.2727272727272727
1973,661 shares,1.2727272727272727
1974,575 shares,1.2727272727272727
1975,028 shares,1.2727272727272727
1976,785 shares,1.2727272727272727
1977,129 shares,1.2727272727272727
1978,088 shares,1.2727272727272727
1979,732 shares,1.2727272727272727
1980,909 shares,1.2727272727272727
1981,091 shares,1.2727272727272727
1982,752 shares,1.2727272727272727
1983,064 shares,1.2727272727272727
1984,687 shares,1.2727272727272727
1985,482 shares,1.2727272727272727
1986,500 shares,1.2727272727272727
1987,333 shares,1.2727272727272727
1988,411 shares,1.2727272727272727
1989,368 shares,1.2727272727272727
1990,150 shares,1.2727272727272727
1991,322 shares,1.2727272727272727
1992,955 shares,1.2727272727272727
1993,893 shares,1.2727272727272727
1994,650 shares,1.2727272727272727
1995,017 shares,1.2727272727272727
1996,67 shares,1.2727272727272727
1997,896 shares,1.2727272727272727
1998,446 shares,1.2727272727272727
1999,443 shares,1.2727272727272727
2000,030 shares,1.2727272727272727
2001,047 shares,1.2727272727272727
2002,767 shares,1.2727272727272727
2003,women,1.2682926829268293
2004,110 women,1.2682926829268293
2005,medicine,1.2666666666666666
2006,3 doses,1.2666666666666666
2007,doses,1.2666666666666666
2008,gog,1.25
2009,filed,1.25
2010,settled,1.25
2011,pre,1.25
2012,investigation,1.25
2013,investigator,1.25
2014,entities,1.25
2015,neoepitopes,1.25
2016,reached,1.25
2017,label,1.2439024390243902
2018,accepted,1.2380952380952381
2019,responsible,1.2307692307692308
2020,high,1.2222222222222223
2021,chancery,1.2222222222222223
2022,evaluate,1.2222222222222223
2023,enroll,1.2222222222222223
2024,axal,1.2210526315789474
2025,entered,1.2205882352941178
2026,commercialization,1.2166666666666666
2027,estimate,1.2142857142857142
2028,immunogenicity,1.2142857142857142
2029,amendments,1.2105263157894737
2030,her2,1.208
2031,controlled,1.2
2032,overview,1.2
2033,september 17,1.2
2034,september,1.2
2035,recognized,1.196078431372549
2036,order,1.1923076923076923
2037,23 order,1.1923076923076923
2038,head,1.1911764705882353
2039,increase,1.1910828025477707
2040,statement,1.1875
2041,discovery,1.1818181818181819
2042,nature,1.1666666666666667
2043,access,1.1666666666666667
2044,circumstances,1.1666666666666667
2045,determination,1.1666666666666667
2046,mine,1.1666666666666667
2047,sellas,1.1666666666666667
2048,consideration,1.16
2049,diagnosed,1.15625
2050,liabilities,1.15625
2051,approximately $39,1.154981549815498
2052,approximately 3,1.154981549815498
2053,approximately 18,1.154981549815498
2054,approximately $8,1.154981549815498
2055,approximately $66,1.154981549815498
2056,approximately $186,1.154981549815498
2057,approximately $418,1.154981549815498
2058,approximately $7,1.154981549815498
2059,approximately 1,1.154981549815498
2060,approximately 25,1.154981549815498
2061,approximately,1.154981549815498
2062,approximately 12,1.154981549815498
2063,approximately 7,1.154981549815498
2064,85%,1.154981549815498
2065,approximately 70,1.154981549815498
2066,approximately 5,1.154981549815498
2067,approximately 22,1.154981549815498
2068,approximately 20,1.154981549815498
2069,approximately 2,1.154981549815498
2070,approximately 600,1.154981549815498
2071,approximately 10,1.154981549815498
2072,approximately 15,1.154981549815498
2073,approximately $6,1.154981549815498
2074,approximately $2,1.154981549815498
2075,approximately $0,1.154981549815498
2076,approximately $1,1.154981549815498
2077,approximately $3,1.154981549815498
2078,approximately $16,1.154981549815498
2079,approximately $9,1.154981549815498
2080,approximately $5,1.154981549815498
2081,approximately $538,1.154981549815498
2082,approximately $614,1.154981549815498
2083,approximately $76,1.154981549815498
2084,approximately $30,1.154981549815498
2085,approximately $28,1.154981549815498
2086,approximately $162,1.154981549815498
2087,approximately $27,1.154981549815498
2088,approximately $10,1.154981549815498
2089,approximately $13,1.154981549815498
2090,approximately $14,1.154981549815498
2091,approximately $4,1.154981549815498
2092,approximately $31,1.154981549815498
2093,approximately $15,1.154981549815498
2094,approximately $528,1.154981549815498
2095,approximately $136,1.154981549815498
2096,approximately $49,1.154981549815498
2097,approximately $53,1.154981549815498
2098,approximately $12,1.154981549815498
2099,11%,1.154981549815498
2100,approximately 60,1.154981549815498
2101,approximately $115,1.154981549815498
2102,approximately $33,1.154981549815498
2103,approximately $89,1.154981549815498
2104,approximately $11,1.154981549815498
2105,75 percent,1.1538461538461537
2106,randomized,1.1538461538461537
2107,91 percent,1.1538461538461537
2108,5 percent,1.1538461538461537
2109,38 percent,1.1538461538461537
2110,subject,1.1515151515151516
2111,attributable,1.1481481481481481
2112,developed,1.1428571428571428
2113,inds,1.1428571428571428
2114,elected,1.1428571428571428
2115,aim2cerv,1.1428571428571428
2116,work,1.1428571428571428
2117,achieving,1.1428571428571428
2118,file,1.1428571428571428
2119,inputs,1.1363636363636365
2120,adxs,1.1358490566037736
2121,6 adxs,1.1358490566037736
2122,7 adxs,1.1358490566037736
2123,cases,1.1333333333333333
2124,allowance,1.125
2125,compared,1.121212121212121
2126,2017 compared,1.121212121212121
2127,months,1.11864406779661
2128,12 months,1.11864406779661
2129,18 months,1.11864406779661
2130,24 months,1.11864406779661
2131,28 months,1.11864406779661
2132,16 months,1.11864406779661
2133,30 months,1.11864406779661
2134,2 months,1.11864406779661
2135,34 months,1.11864406779661
2136,inception,1.1176470588235294
2137,operations,1.116504854368932
2138,assumptions,1.1111111111111112
2139,7 million,1.108974358974359
2140,6 million,1.108974358974359
2141,8 million,1.108974358974359
2142,1 million,1.108974358974359
2143,09 million,1.108974358974359
2144,22 million,1.108974358974359
2145,2 million,1.108974358974359
2146,0 million,1.108974358974359
2147,5 million,1.108974358974359
2148,3 million,1.108974358974359
2149,9 million,1.108974358974359
2150,$40 million,1.108974358974359
2151,$25 million,1.108974358974359
2152,4 million,1.108974358974359
2153,$358 million,1.108974358974359
2154,$1 million,1.108974358974359
2155,$10 million,1.108974358974359
2156,made,1.105263157894737
2157,dual,1.1
2158,forward,1.0952380952380953
2159,spa,1.0769230769230769
2160,decrease,1.0769230769230769
2161,develop,1.0666666666666667
2162,initiate,1.064516129032258
2163,open,1.0526315789473684
2164,public,1.0454545454545454
2165,february 2016,1.037037037037037
2166,february 12,1.037037037037037
2167,february 3,1.037037037037037
2168,february 2015,1.037037037037037
2169,february 27,1.037037037037037
2170,keytruda,1.032258064516129
2171,january 8,1.0285714285714285
2172,january 2015,1.0285714285714285
2173,january 29,1.0285714285714285
2174,january 31,1.0285714285714285
2175,january 9,1.0285714285714285
2176,january 2017,1.0285714285714285
2177,merck,1.025
2178,merck,1.025
2179,item,1.0
2180,listeria,1.0
2181,bioengineered,1.0
2182,believed,1.0
2183,activate,1.0
2184,equivalent,1.0
2185,enable,1.0
2186,shown,1.0
2187,addition,1.0
2188,persistent,1.0
2189,proceed,1.0
2190,advance,1.0
2191,ema,1.0
2192,evaluated,1.0
2193,medimmune,1.0
2194,llc,1.0
2195,durvalumab,1.0
2196,medi4736,1.0
2197,iii,1.0
2198,gbp,1.0
2199,asia,1.0
2200,pembrolizumab,1.0
2201,gastric,1.0
2202,newly,1.0
2203,surgically,1.0
2204,agriculture,1.0
2205,usda,1.0
2206,areas,1.0
2207,october,1.0
2208,put,1.0
2209,submission,1.0
2210,discussions,1.0
2211,accordance,1.0
2212,recommendations,1.0
2213,implement,1.0
2214,post,1.0
2215,december,1.0
2216,lifted,1.0
2217,respect,1.0
2218,focused,1.0
2219,establishing,1.0
2220,incorporates,1.0
2221,commercialized,1.0
2222,invest,1.0
2223,exploration,1.0
2224,expanding,1.0
2225,mutation,1.0
2226,epitopes,1.0
2227,lastly,1.0
2228,liquidity,1.0
2229,result,1.0
2230,continue,1.0
2231,april,1.0
2232,fund,1.0
2233,prove,1.0
2234,wrong,1.0
2235,uncertainties,1.0
2236,unable,1.0
2237,completing,1.0
2238,execute,1.0
2239,assurance,1.0
2240,profitable,1.0
2241,summary,1.0
2242,prepared,1.0
2243,america,1.0
2244,rules,1.0
2245,regulations,1.0
2246,sec,1.0
2247,form 10,1.0
2248,rule 10,1.0
2249,regulation,1.0
2250,adjustments,1.0
2251,consisting,1.0
2252,opinion,1.0
2253,represent,1.0
2254,read,1.0
2255,conjunction,1.0
2256,october,1.0
2257,derived,1.0
2258,derive,1.0
2259,majority,1.0
2260,perpetual,1.0
2261,renew,1.0
2262,determinable,1.0
2263,delivery,1.0
2264,occurred,1.0
2265,collectability,1.0
2266,assured,1.0
2267,charged,1.0
2268,means,1.0
2269,collection,1.0
2270,exhausted,1.0
2271,recovery,1.0
2272,occur,1.0
2273,successful,1.0
2274,licensees,1.0
2275,achievability,1.0
2276,preparation,1.0
2277,affect,1.0
2278,recoverability,1.0
2279,licenses,1.0
2280,reclassifications,1.0
2281,reclassified,1.0
2282,conform,1.0
2283,concentration,1.0
2284,checking,1.0
2285,maintained,1.0
2286,exposed,1.0
2287,computed,1.0
2288,case,1.0
2289,computation,1.0
2290,directors,1.0
2291,consultants,1.0
2292,depending,1.0
2293,estimating,1.0
2294,judgments,1.0
2295,referred,1.0
2296,charge,1.0
2297,convergence,1.0
2298,customers,1.0
2299,goods,1.0
2300,reflects,1.0
2301,timing,1.0
2302,uncertainty,1.0
2303,adopted,1.0
2304,july,1.0
2305,deferral,1.0
2306,defers,1.0
2307,december,1.0
2308,clarifies,1.0
2309,april,1.0
2310,narrow,1.0
2311,amend,1.0
2312,aspects,1.0
2313,utilize,1.0
2314,simplify,1.0
2315,subtopic 225,1.0
2316,eliminating,1.0
2317,concept,1.0
2318,transactions,1.0
2319,distinguished,1.0
2320,infrequency,1.0
2321,deleted,1.0
2322,quarter,1.0
2323,permitted,1.0
2324,topic,1.0
2325,applied,1.0
2326,outlined,1.0
2327,long,1.0
2328,penn,1.0
2329,passed,1.0
2330,expirations,1.0
2331,expired,1.0
2332,converted,1.0
2333,issuance,1.0
2334,method,1.0
2335,calculate,1.0
2336,gain,1.0
2337,determining,1.0
2338,exercised,1.0
2339,daniel,1.0
2340,connor,1.0
2341,gregory,1.0
2342,mayes,1.0
2343,robert,1.0
2344,petit,1.0
2345,sara,1.0
2346,bonstein,1.0
2347,secretary,1.0
2348,present,1.0
2349,october,1.0
2350,executives,1.0
2351,board,1.0
2352,delivered,1.0
2353,contingencies,1.0
2354,august 21,1.0
2355,existence,1.0
2356,alternatively,1.0
2357,breach,1.0
2358,august 31,1.0
2359,october,1.0
2360,dismiss,1.0
2361,october,1.0
2362,motion,1.0
2363,answer,1.0
2364,defend,1.0
2365,july,1.0
2366,officers,1.0
2367,del,1.0
2368,behalf,1.0
2369,named,1.0
2370,august 20,1.0
2371,district,1.0
2372,flw,1.0
2373,dea,1.0
2374,aug,1.0
2375,breaches,1.0
2376,violation,1.0
2377,disgorgement,1.0
2378,actions,1.0
2379,members,1.0
2380,denying,1.0
2381,prejudice,1.0
2382,proceeding,1.0
2383,express,1.0
2384,ordinary,1.0
2385,duration,1.0
2386,covers,1.0
2387,mexico,1.0
2388,brazil,1.0
2389,colombia,1.0
2390,manage,1.0
2391,promotion,1.0
2392,located,1.0
2393,princeton,1.0
2394,strengthen,1.0
2395,scheduled,1.0
2396,expire,1.0
2397,november,1.0
2398,increments,1.0
2399,remainder,1.0
2400,august 2016,1.0
2401,laboratories,1.0
2402,asset,1.0
2403,transfer,1.0
2404,buyers,1.0
2405,sellers,1.0
2406,knowledgeable,1.0
2407,transact,1.0
2408,indirectly,1.0
2409,corroborated,1.0
2410,supported,1.0
2411,15 item,1.0
2412,discussion,1.0
2413,expectations,1.0
2414,happen,1.0
2415,incorporated,1.0
2416,reference,1.0
2417,appearing,1.0
2418,protect,1.0
2419,infected,1.0
2420,challenges,1.0
2421,acceptance,1.0
2422,accessibility,1.0
2423,compliance,1.0
2424,vaccinated,1.0
2425,world,1.0
2426,india,1.0
2427,asco,1.0
2428,sae,1.0
2429,resolved,1.0
2430,purpose,1.0
2431,incorporate,1.0
2432,integrity,1.0
2433,field,1.0
2434,bla,1.0
2435,territories,1.0
2436,takes,1.0
2437,recur,1.0
2438,goal,1.0
2439,dcgi,1.0
2440,driven,1.0
2441,proof,1.0
2442,companies,1.0
2443,gained,1.0
2444,astrazeneca,1.0
2445,multicenter,1.0
2446,cervix,1.0
2447,member,1.0
2448,sponsorship,1.0
2449,ctep,1.0
2450,nci,1.0
2451,component,1.0
2452,agos,1.0
2453,2 fatigue,1.0
2454,chills,1.0
2455,fever,1.0
2456,october,1.0
2457,evaluation,1.0
2458,morbidity,1.0
2459,pharynx,1.0
2460,larynx,1.0
2461,epidemiology,1.0
2462,surgery,1.0
2463,window,1.0
2464,opportunity,1.0
2465,aacr,1.0
2466,april,1.0
2467,cd4,1.0
2468,cd8,1.0
2469,reduction,1.0
2470,fluctuations,1.0
2471,tnfa,1.0
2472,mip,1.0
2473,activated,1.0
2474,migration,1.0
2475,collaborate,1.0
2476,linked,1.0
2477,foregoing,1.0
2478,rtog,1.0
2479,conduct,1.0
2480,leading,1.0
2481,taiwan,1.0
2482,china,1.0
2483,histologically,1.0
2484,nsclc,1.0
2485,adenocarcinoma,1.0
2486,comprises,1.0
2487,smoked,1.0
2488,important,1.0
2489,prevalence,1.0
2490,planning,1.0
2491,man,1.0
2492,lifetime,1.0
2493,die,1.0
2494,castration,1.0
2495,overexpressed,1.0
2496,percentage,1.0
2497,bladder,1.0
2498,brain,1.0
2499,pancreatic,1.0
2500,ovarian,1.0
2501,cleared,1.0
2502,intend,1.0
2503,400 children,1.0
2504,teens,1.0
2505,decades,1.0
2506,qualify,1.0
2507,affecting,1.0
2508,accelerated,1.0
2509,85%,1.0
2510,older,1.0
2511,lameness,1.0
2512,leg,1.0
2513,diagnosis,1.0
2514,ten,1.0
2515,analgesics,1.0
2516,direction,1.0
2517,determine,1.0
2518,safe,1.0
2519,hematological,1.0
2520,delay,1.0
2521,615 days,1.0
2522,956 days,1.0
2523,423 days,1.0
2524,unsuitable,1.0
2525,animals,1.0
2526,survivin,1.0
2527,focus,1.0
2528,learnings,1.0
2529,identify,1.0
2530,msk,1.0
2531,triple,1.0
2532,amenable,1.0
2533,estrogen,1.0
2534,progesterone,1.0
2535,presence,1.0
2536,resistance,1.0
2537,attractive,1.0
2538,/target,1.0
2539,academic,1.0
2540,centers,1.0
2541,clinically,1.0
2542,expensed,1.0
2543,distribute,1.0
2544,approved,1.0
2545,finance,1.0
2546,held,1.0
2547,expiration,1.0
2548,inducing,1.0
2549,noteholders,1.0
2550,convert,1.0
2551,discount,1.0
2552,receipt,1.0
2553,connection,1.0
2554,excess,1.0
2555,10 liquidity,1.0
2556,ability,1.0
2557,marketplace,1.0
2558,overcome,1.0
2559,impose,1.0
2560,partnership,1.0
2561,begin,1.0
2562,operate,1.0
2563,cleanroom,1.0
2564,enter,1.0
2565,vendors,1.0
2566,cancelable,1.0
2567,obligated,1.0
2568,achievement,1.0
2569,estimable,1.0
2570,expose,1.0
2571,engages,1.0
2572,leasing,1.0
2573,hedging,1.0
2574,uncertain,1.0
2575,selected,1.0
2576,differences,1.0
2577,intangibles,1.0
2578,discusses,1.0
2579,designated,1.0
2580,classified,1.0
2581,atmp,1.0
2582,august,1.0
2583,august 19,1.0
2584,july,1.0
2585,june,1.0
2586,topic,1.0
2587,aren,1.0
2588,simplifies,1.0
2589,loans,1.0
2590,activates,1.0
2591,respond,1.0
2592,mid,1.0
2593,/kg,1.0
2594,/kg,1.0
2595,advancing,1.0
2596,show,1.0
2597,worth,1.0
2598,vaccine,1.0
2599,induced,1.0
2600,center,1.0
2601,fawcett,1.0
2602,weeks,1.0
2603,ways,1.0
2604,exploit,1.0
2605,simon,1.0
2606,europe,1.0
2607,comparing,1.0
2608,leveraging,1.0
2609,shared,1.0
2610,hotspots,1.0
2611,exploring,1.0
2612,build,1.0
2613,collectible,1.0
2614,conditions,1.0
2615,nonrefundable,1.0
2616,relation,1.0
2617,priced,1.0
2618,october,1.0
2619,reconsideration,1.0
2620,galinpepimut,1.0
2621,14 item,1.0
2622,suitable,1.0
2623,blind,1.0
2624,hrlacc,1.0
2625,compare,1.0
2626,radiotherapy,1.0
2627,ccrt,1.0
2628,sitc,1.0
2629,10 mg/kg,1.0
2630,nausea,1.0
2631,hypotension,1.0
2632,accrual,1.0
2633,frequency,1.0
2634,severity,1.0
2635,prospectively,1.0
2636,robust,1.0
2637,comparator,1.0
2638,progress,1.0
2639,0265 comprise,1.0
2640,50 subjects,1.0
2641,calculated,1.0
2642,october,1.0
2643,sgo,1.0
2644,assessing,1.0
2645,atmps,1.0
2646,underway,1.0
2647,december,1.0
2648,agree,1.0
2649,budget,1.0
2650,simon,1.0
2651,cohorts,1.0
2652,begun,1.0
2653,analyzed,1.0
2654,understand,1.0
2655,presenting,1.0
2656,stimulating,1.0
2657,tesla,1.0
2658,initiative,1.0
2659,shelf,1.0
2660,ready,1.0
2661,administer,1.0
2662,explore,1.0
2663,dtllo,1.0
2664,carrier,1.0
2665,vaccinations,1.0
2666,categorized,1.0
2667,invested,1.0
2668,bristol,1.0
2669,bms,1.0
2670,opdivo,1.0
2671,nivolumab,1.0
2672,asc,1.0
2673,topic,1.0
2674,facts,1.0
2675,reevaluates,1.0
2676,roles,1.0
2677,exposure,1.0
2678,endeavor,1.0
2679,refundable,1.0
2680,guarantee,1.0
2681,technological,1.0
2682,topic,1.0
2683,topic,1.0
2684,clarifying,1.0
2685,definition,1.0
2686,acquisitions,1.0
2687,disposals,1.0
2688,businesses,1.0
2689,screen,1.0
2690,removes,1.0
2691,diversity,1.0
2692,practice,1.0
2693,complexity,1.0
2694,applying,1.0
2695,counted,1.0
2696,receivables,1.0
2697,lieu,1.0
2698,april,1.0
2699,matter,1.0
2700,insurance,1.0
2701,admission,1.0
2702,wrongdoing,1.0
2703,solely,1.0
2704,avoiding,1.0
2705,inconvenience,1.0
2706,resolution,1.0
2707,stipulation,1.0
2708,dismissal,1.0
2709,khleif,1.0
2710,mckearn,1.0
2711,patton,1.0
2712,mauro,1.0
2713,april,1.0
2714,principle,1.0
2715,negotiating,1.0
2716,attorneys,1.0
2717,plaintiffs,1.0
2718,counsel,1.0
2719,november,1.0
2720,assessed,1.0
2721,orr,1.0
2722,fatigue,1.0
2723,anemia,1.0
2724,eighteen,1.0
2725,3 weeks,1.0
2726,1 post,1.0
2727,indicating,1.0
2728,rigors,1.0
2729,vomiting,1.0
2730,1 sae,1.0
2731,esmo,1.0
2732,secretes,1.0
2733,building,1.0
2734,bear,1.0
2735,sponsor,1.0
2736,adxs31,1.0
2737,priorities,1.0
2738,half,1.0
2739,august 2017,1.0
